Clinical Practice Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Mar 14, 2018; 24(10): 1152-1166
Published online Mar 14, 2018. doi: 10.3748/wjg.v24.i10.1152
Figure 2
Figure 2 PGRMC1 and PGRMC2 expression levels, expressed as positive immunohistochemical staining percentages in the clinical cohort (A and B) and as normalized mRNA expression in the TCGA cohort (C-F). A: A comparison of PGRMC1 and PGRMC2 staining in HCC (T), non-tumor liver (NT) and normal liver (N) tissue samples; B: A comparison of PGRMC1 staining in HCC samples with different degrees of tumor differentiation; C: A comparison of PGRMC1 and PGRMC2 mRNA expression levels in HCC (T) and non-tumor liver (NT) samples; D: A comparison of PGRMC1 mRNA expression levels in HCC samples with different tumor grades; E: A comparison of PGRMC1 mRNA expression levels in HCC samples with different tumor stages; F: A comparison of PGRMC2 mRNA expression levels in HCC samples with different tumor grades. aP < 0.05, bP < 0.01, eP < 0.001.